May 23, 2022
Via: FierceBiotechHolding company Innoviva is acquiring late-stage antibiotic biotech Entasis Therapeutics, a 2015 AstraZeneca spin-out that just posted phase 3 results worthy of an FDA filing last year. Innoviva already owns about 60% of Entasis’ outstanding shares. Under the new definitive […]
July 19, 2024
July 11, 2024
July 11, 2024